Navigation Links
Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan

LONDON, July 25, 2012 /PRNewswire/ -- The prefillable syringes (PFS) market in Europe is growing due to the convenience, efficiency, and safety PFS offers. There is an increasing use of PFS in high-cost drug applications as well, in order to contain wastage. Most of the Europe-based PFS manufacturers have either expanded their capacity or are planning further capacity expansion in the next two or three years. For now, the market is dominated by Becton, Dickinson and Company (BD), which accounts for a market share of approximately 70 per cent.

New analysis from Frost & Sullivan (, Analysis of the European Prefillable Syringes Market, finds that the total European demand for glass prefillable syringes for all therapeutic applications combined was roughly 1.63 billion units in 2011. The demand for PFS is expected to grow to approximately 3.62 billion units by 2018 in Europe at a CAGR of 10.3 per cent.

"The major growth drivers for PFS are factors such as convenience for healthcare professionals and patients, enhanced product differentiation, lower overfill which helps reduce costs and maximise yield, reduced risk of dosage error and contamination," noted Frost & Sullivan Program Manager Ranjith Gopinathan. "Moreover, increasing use of biologics as a therapy for various disease indications has bolstered the growth of parenteral delivery."

There is considerable demand for syringes with safety features. Safety syringes like the Luer lock or syringes with additional safety features are gaining favourable opinion among policy makers and healthcare providers in Europe. Conversion to devices with safety features would drive demand growth for PFS.

However, cost is a major restraining factor for PFS demand. Cost of prefillable syringes is higher when compared to other delivery routes such as vials and ampoules. Moreover, safety-enabled syringes like Luer lock and those with proprietary safety features have premium pricing.

Nevertheless, the strong growth in the self-injection market, preference for added safety features and the growing market for seasonal influenza vaccines, pitch a strong case for PFS demand. Furthermore, new regulatory norms require drugs with shelf life of more than two years, to be in glass PFS.

"Overall, PFS with customised dimensions, competitive pricing, product innovation with focus on safety features and timely delivery would be key success factors for market participants," summarises Gopinathan.

If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at

Analysis of the European Prefillable Syringes Market is part of the Life Sciences Growth Partnership Service programme, which also includes research in the following markets: Analysis of the European Thrombosis Therapeutics Market, European Vaccines Market, among others. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:        Newsletter on "the next big thing"
Register:          Gain access to visionary innovation

Analysis of the European Prefillable Syringes Market

Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. Anoto Digital Pen and Paper Facilitating Adoption of Meaningful Use Certified Electronic Health Record Technology
3. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
6. CHPA Applauds Alabamas Adoption Of HB 363
7. BD Announces Agreement to Acquire Safety Syringes, Inc.
8. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
9. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
10. Radiotherapy Devices Market By Technology, Applications & Products (2011 - 2016)
11. Frost & Sullivan: Label-Free Technology is a High Potential Market with Myriad Unexplored Applications
Post Your Comments:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):